Vaginal lubricants are widely used by women to help solve intercourse difficulties or as enhancers, but recent reports raise questions about their safety. Twelve commercially available gel products were tested for pH value, pH buffering capacity, osmolality and cytotoxicity relevant to vaginal delivery. Obtained data were analyzed in light of the recent Advisory Note by the World Health Organization (WHO) for personal lubricants to be concomitantly used with condoms. Results showed that most products do not comply with pH and osmolality recommended standards, thus posing a potential hazard. Four products presented values of osmolality around three-times higher than the maximum acceptable limit of 1200 mOsm/kg. In vitro cell testing further identified substantial cytotoxicity even at 1:100 dilutions for three products, contrasting with no significant effect of up to at least a 1:5 dilution of a Universal Placebo gel. However, no direct correlation between these last results and pH or osmolality was found, thus suggesting that the individual toxicity of specific formulation components plays an important role in the outcome of a particular product. Although further assessment is required, these results highlight potential safety issues related to the formulation of commercially available vaginal lubricants.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190534 | PMC |
http://dx.doi.org/10.3390/pharmaceutics6030530 | DOI Listing |
Expert Opin Pharmacother
January 2025
Femicare vzw, Tienen, Belgium.
Introduction: Vulvovaginal atrophy (VVA) predominantly affects postmenopausal women due to hormonal decline but can also occur in premenopausal women with conditions such as primary ovarian insufficiency or exposure to anti-estrogen medications. Contributing factors include smoking and certain medical treatments. Symptoms like dyspareunia and loss of sexual function affect many women but are underreported due to stigma and lack of awareness.
View Article and Find Full Text PDFCureus
December 2024
Department of Aesthetic and Anti-Aging Medicine, Central Medica Quirurgica, Mazatlan, MEX.
Background Female sexual dysfunction (FSD) affects a significant portion of the female population, negatively impacting quality of life. New therapeutic approaches, such as the combination of laser therapy and platelet-rich plasma (PRP), are being explored as potential treatments to enhance sexual function in affected women. Methods This original study involved 23 women aged 37 to 72, all diagnosed with varying degrees of FSD (mild, moderate, severe).
View Article and Find Full Text PDFAm J Obstet Gynecol
December 2024
Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA; Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address:
Int Urogynecol J
December 2024
Faculty of Medicine, Isfahan University of Medical Science, Isfahan, Iran.
Introduction And Hypothesis: Vaginismus is characterized by the involuntary spasm of the pelvic floor muscles (PFMs) around the outer third of the vagina, leading to difficulties in vaginal penetration. Physical therapists often use biofeedback to help individuals to gain better control over their muscles. This study was aimed at assessing the impact of biofeedback with dilator therapy on sexual function in women with primary vaginismus.
View Article and Find Full Text PDFGenito-pelvic pain/penetration disorder is a relatively new term encompassing both dyspareunia (recurrent pain with intercourse) and vaginismus (involuntary contraction of the pelvic floor with attempted penetration). Symptoms are often multifactorial. Thus, a detailed history and sensitive patient-centered examination are essential to identify and treat the underlying cause(s).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!